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Never was Presented Elsewhere
We present a case report of a complete response to a combination of trastuzumab and pegylated liposomal 
doxorubicin in a female patient with recurrent metastatic HER-2 positive breast cancer after anthracy-
cline-based adjuvant primary chemotherapy. To our knowledge this sequence of events has not previ-
ously been reported.
In September 2003, after routine mammographic detection, this 59-year-old business executive 
mother of two underwent right mastectomy and axillary node dissection with immediate reconstruction. 
Pathologic diagnosis included a T1N0M0 poorly differentiated inﬁ  ltrating ductal carcinoma and further 
characterized by high proliferative fraction, negative hormone receptors, 3+ Her2 expression by immu-
nohistochemistry, and 8-fold ampliﬁ  cation of Her2 by FISH. Entry into Intergroup Study N9831 (1) 
was precluded by presumed pressure related brachial paresis during her postoperative recovery. Her 
adjuvant chemotherapy consisted of four cycles of doxorubicin (60 mg/m
2) + cyclophosphamide 
(600 mg/m
2) on a dose-dense (biweekly) schedule with G-CSF, followed by 7 doses of paclitaxel 
(100 mg/m
2) every 10 to 11 days (without growth factors). She remained well for one and a half years, 
when lumbo-sacral and lower thoracic pain while exercising prompted a bone scan showing multiple 
lesions. PET/CT (Fig. 1a) conﬁ  rmed bone scan ﬁ  ndings and in addition showed liver involvement. 
Physical examination was unchanged, and cancer antigen (Ca 27.29) remained normal.
Treatment with trastuzumab (loading dose 8 mg/kg and subsequently 6 mg/kg) every three weeks, 
combined with pegylated liposomal doxorubicin (Doxil) 30 mg/m2 every three weeks was instituted, based 
on causing the least disruption of her daily activities, and on our institutional study (2,3). A baseline left 
ventricular ejection fraction by MUGA was 70% and unchanged 9 and 18 weeks later. Zoledronate 4 mg 
IV was added and repeated every 6–9 weeks. With appearance of grade 2 hand-foot skin changes after the 
third dose, Doxil was then given at a 6-week interval. A follow-up PET/CT shows bone sclerosis, with no 
uptake of 18F-ﬂ  uoro-deoxyglucose (Fig. 1b). She will continued to receive trastuzumab 6 mg/kg every 
3 weeks and Doxil 30 mg/m2 every 6 weeks in the absence of disease progression or adverse events.
Human epidermal growth factor receptor 2( HER2) gene ampliﬁ  cation, found in 25% of primary 
breast tumors, is associated with an aggressive course and shortened overall survival (4) that has been 
known to improve with anthracycline-based therapy (5). Recently, this has been attributed to the frequent 
co-ampliﬁ  cation of the topoisomerase 2 gene that is located in the same chromosome as Her2 (6). 
Trastuzumab, a humanized monoclonal antibody against the HER2 protein was shown in 2001 to sig-
niﬁ  cant improve the survival of women treated for HER2 overexpressing metastatic breast cancer when 
combined with doxorubicin and cyclophosphamide (ﬁ  rst-line) or paclitaxel (second-line)(7). An unex-
pected ﬁ  nding was the enhancement of anthracycline (doxorubicin) cardiac toxicity by concomitant 
trastuzumab (8), and this combination was subsequently avoided, except in clinical studies evaluating 
combinations with the less cardiotoxic epirubicin (9) or the pegylated liposomal formulation Doxil 
(2,3). Therefore there was a clear rationale to investigate the safety and efﬁ  cacy of this combination in 
the clinical setting. A 52% overall response rate and cardiac safety was reported with Doxil and 
Trastuzumab in 42 patients with overexpressing HER2 metastatic breast cancer (2).470 Clinical Medicine: Oncology 2008: 2
Strategies for treatment of HER-2 positive 
breast cancer are evolving (10) and this is exempli-
ﬁ  ed by this patient. In addition, this remarkable 
complete response (CR) by PET/CT suggests that 
such documented CRs may not only become more 
common, but offer a potential surrogate endpoint 
of comparative efﬁ  cacy in the study of ﬁ  rst-line or 
neoadjuvant regimens for this disease.
One year after onset of treatment, a routine 
repeat PET/CT documented reactivation of 18F-
ﬂ  uorodeoxyglucose (FDG) uptake in a 1 cm area 
in the left ischium. Assessment of the central 
nervous system by MRI documented 5 lesions in 
various areas of the cerebrum measuring from 
2–3 mm without edema. Accordinly, in February 
2007 she was treated with stereotactic (gamma-
knife) radiation of these lesions, and she is being 
treated with capecitabine + lapatinib.
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